TrialPigment cell & melanoma research2018

A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma.

Janice M Mehnert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.